Market closed

AnaptysBio/$ANAB

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Ticker

$ANAB
Trading on

Industry

Biotechnology

Employees

117

AnaptysBio Metrics

BasicAdvanced
$618M
Market cap
-
P/E ratio
-$6.04
EPS
-0.24
Beta
-
Dividend rate
$618M
-0.24
$41.31
$13.36
522K
10.225
10.08
432.836
435.073
-3.72%
-17.85%
-161.81%
9.738
7.33
7.33
-5.385
282.17%
11.88%
-22.36%
170.22%

What the Analysts think about AnaptysBio

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for AnaptysBio stock.

AnaptysBio Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AnaptysBio Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ANAB

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for AnaptysBio stock?

AnaptysBio (ANAB) has a market cap of $618M as of November 22, 2024.

What is the P/E ratio for AnaptysBio stock?

The price to earnings (P/E) ratio for AnaptysBio (ANAB) stock is 0 as of November 22, 2024.

Does AnaptysBio stock pay dividends?

No, AnaptysBio (ANAB) stock does not pay dividends to its shareholders as of November 22, 2024.

When is the next AnaptysBio dividend payment date?

AnaptysBio (ANAB) stock does not pay dividends to its shareholders.

What is the beta indicator for AnaptysBio?

AnaptysBio (ANAB) has a beta rating of -0.24. This means that it has an inverse relation to market volatility.